Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS Research and Therapy
Published in: AIDS Research and Therapy 1/2022

Open Access 01-12-2022 | Human Immunodeficiency Virus | Research

Prevalence and risk factors of high cholesterol and triglycerides among people with HIV in Texas

Authors: Justin Buendia, Sabeena Sears, Osaro Mgbere

Published in: AIDS Research and Therapy | Issue 1/2022

Login to get access

Abstract

Background

People with HIV (PWH) commonly have elevated cholesterol and triglycerides levels that have been linked to medications. However, healthy behaviors including lifestyle changes can lower high cholesterol (CHOL) or high triglycerides (TG), thereby reducing individual risk for cardiovascular diseases. This study aimed to determine the prevalence and risk factors associated with high CHOL or TG among PWH in Texas.

Methods

Cross-sectional data of 981 PWH from the 2015–2017 Texas and Houston Medical Monitoring Projects were examined. High CHOL or TG was identified by medical chart diagnosis, CHOL or TG medication use, or most recent fasting lab ≥ 200 mg/dl (total CHOL) or ≥ 150 mg/dl (TG). High CHOL or TG associations with sociodemographic and clinical characteristics were assessed using Rao-Scott chi-square tests. Prevalence of high CHOL or TG development was calculated using multivariable logistic regression model.

Results

High CHOL or TG prevalence was 41% with participants being mostly male (73%), ≥ 40 years (68%), with overweight (31%) or obesity (28%), and virally suppressed (62%). Compared with PWH < 40 years of age, PWH in their 40s, 50s, and ≥ 60s were 57%, 64%, and 62% more likely to have high CHOL or TG, respectively. Participants with overweight and obesity were 41% and 30% more likely to have high CHOL or TG than those with normal weight (BMI: 18.5– < 25), respectively.

Conclusion

Since high CHOL and TG are modifiable CVD risk factors, increased education and lifestyle modification interventions are warranted to prevent the development of high CHOL or TG among PWH.
Appendix
Available only for authorised users
Literature
1.
Collaboration ATC. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet. 2008;372:293–9.CrossRef
2.
Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002;16:1663–71.PubMedCrossRef
3.
Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States. NCHS Data Brief. 2017;2018:1–8.
4.
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62.PubMedCrossRef
5.
6.
Shah AS, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138:1100–12.PubMedPubMedCentralCrossRef
7.
Hsue PY, Waters DD. Time to recognize HIV infection as a major cardiovascular risk factor. Am Heart Assoc. 2018;138:1113–5.
8.
Carroll MD, Fryar CD, Nguyen DT and Statistics NCfH. Total and high-density lipoprotein cholesterol in adults: United States, 2015–2016. US Department of Health and Human Services, Centers for Disease Control and Prevention. 2017.
9.
Rader DJ, Hovingh GK. HDL and cardiovascular disease. The Lancet. 2014;384:618–25.CrossRef
10.
11.
12.
13.
Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–9.PubMedCrossRef
14.
Cardiovascular Disease: A Costly Burden for America Projections Through 2035 (pp. 6–11, Rep. No. American Heart Association CVD Burden Report). (2017). Washington, DC: The American Heart Association Office of Federal Advocacy.
15.
Kuklina EV, Yoon PW, Keenan NL. Prevalence of coronary heart disease risk factors and screening for high cholesterol levels among young adults, United States, 1999–2006. The Annals of Family Medicine. 2010;8:327–33.PubMedCrossRef
16.
Lepor NE, Vogel RE. Summary of the third report of the national cholesterol education program adult treatment panel III. Rev Cardiovasc Med. 2019;2:160–5.
17.
Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130–9.PubMedCrossRef
18.
Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals–focus on protease inhibitor therapy. AIDS. 2001;15:329–34.PubMedCrossRef
19.
Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63–70.PubMedCrossRef
20.
Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–8.PubMedCrossRef
21.
Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167–73.PubMedCrossRef
22.
Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100:700–5.PubMedCrossRef
23.
Capeau J, Bouteloup V, Katlama C, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26:303–14.PubMedCrossRef
24.
Waters DD, Hsue PY. Lipid abnormalities in persons living with HIV infection. Can J Cardiol. 2019;35:249–59.PubMedCrossRef
25.
26.
Reif SS, Whetten K, Wilson ER, et al. HIV/AIDS in the Southern USA: a disproportionate epidemic. AIDS Care. 2014;26:351–9.PubMedCrossRef
27.
Reif S, Safley D, McAllaster C, Wilson E, Whetten K. State of HIV in the US Deep South. J Community Health. 2017;42:844–53.PubMedCrossRef
28.
Definitions S. Final dispositions of case codes and outcome rates for surveys. The American Association for Public Opinion Research. 2011.
29.
Heeringa SG, West BT, Berglund PA. Applied survey data analysis. Boca Raton: Chapman and Hall/CRC; 2017.
30.
Control CfD and Prevention. Vital signs: binge drinking prevalence, frequency, and intensity among adults-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:14.
31.
Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114:163–73.PubMedCrossRef
32.
Armah K, Justice A, Oursler K, et al. The impact of elevated and prehypertensive systolic blood pressure and the risk of acute myocardial infarction in HIV+ and HIV-veterans. 19th Conference on Retroviruses and Oppotunistic Infections CROI. 2012.
33.
Glass T, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006;7:404–10.PubMedCrossRef
34.
35.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72. https://​doi.​org/​10.​1001/​jama.​289.​19.​2560 (Epub 2003 May 14. Erratum in: JAMA. 2003 Jul 9;290(2):197).CrossRefPubMed
36.
Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45:1074–81.PubMedCrossRef
37.
Cioe PA, Crawford SL, Stein MD. Cardiovascular risk-factor knowledge and risk perception among HIV-infected adults. J Assoc Nurses AIDS Care. 2014;25:60–9.PubMedCrossRef
38.
Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–93.PubMedCrossRef
39.
Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS. 2001;15:725–34.PubMedCrossRef
40.
Blann AD, Farrell A, Picton A, McCollum CN. Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease. Thromb Res. 2000;97:209–16.PubMedCrossRef
41.
42.
Foulkes AS, Wohl DA, Frank I, et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006;3: e52.PubMedPubMedCentralCrossRef
43.
Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137: e67.PubMedCrossRef
44.
Appel SJ, Harrell JS, Deng S. Racial and socioeconomic differences in risk factors for cardiovascular disease among Southern rural women. Nurs Res. 2002;51:140–7.PubMedCrossRef
45.
Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–84.PubMedCrossRef
46.
De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D: A: D) study. Diabetes Care. 2008;31:1224–9.PubMedCrossRef
47.
Rasmussen LD, Mathiesen ER, Kronborg G, Gerstoft J, Obel N. Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS ONE. 2012;7: e44575.PubMedPubMedCentralCrossRef
48.
Polsky S, Floris-Moore M, Schoenbaum EE, Klein RS, Arnsten JH, Howard AA. Incident hyperglycaemia among older adults with or at-risk for HIV infection. Antivir Ther. 2011;16:181.PubMedPubMedCentralCrossRef
49.
50.
Leyes P, Cofan M, González-Cordón A, et al. Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. AIDS. 2018;32:1309–16.PubMedCrossRef
51.
Fontas E, Van Leth F, Sabin C, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056–74.PubMedCrossRef
52.
Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A: D) study. J Infect Dis. 2010;201:318–30.PubMedCrossRef
53.
Ucciferri C, Falasca K, Vignale F, Di Nicola M, Pizzigallo E, Vecchiet J. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol. 2013;85:755–9.PubMedCrossRef
54.
Srinivasa S, Grinspoon SK. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. Eur J Endocrinol. 2014;170:R185-202.PubMedCrossRef
55.
Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. The Lancet. 2013;381:735–43.CrossRef
56.
Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima–media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS. 2005;19:927.PubMedCrossRef
57.
Chironi G, Escaut L, Gariepy J, et al. Carotid intima-media thickness in heavily pretreated HIV-infected patients. JAIDS J Acquir Immune Defic Syndr. 2003;32:490–3.PubMedCrossRef
58.
Mercié P, Thiébaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med. 2002;34:55–63.PubMedCrossRef
59.
Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.PubMedCrossRef
60.
61.
Maisa A, Hearps AC, Thomas AA, et al. Monocytes from HIV+ individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration. AIDS. 2015;29:1445.PubMedCrossRef
62.
May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011;343: d6016.PubMedPubMedCentralCrossRef
63.
Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435–47.PubMedCrossRef
64.
Tort O, Escribà T, Egaña-Gorroño L, et al. Cholesterol efflux responds to viral load and CD4 counts in HIV+ patients and is dampened in HIV exposed. J Lipid Res. 2018;59:2108–15.PubMedPubMedCentralCrossRef
65.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMedCrossRef
66.
Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp. 2013;61:119–25.CrossRef
67.
68.
Administration HRS. HIV/AIDS Bureau Performance Measures. 2019.
69.
70.
Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790–7.PubMedCrossRef
Metadata
Title
Prevalence and risk factors of high cholesterol and triglycerides among people with HIV in Texas
Authors
Justin Buendia
Sabeena Sears
Osaro Mgbere
Publication date
01-12-2022
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2022
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-022-00467-y

Other articles of this Issue 1/2022

AIDS Research and Therapy 1/2022 Go to the issue

Case Report

Central nervous system aspergillosis misdiagnosed as Toxoplasma gondii encephalitis in a patient with AIDS: a case report

Research

Comparison of predictors for early and late mortality in adults commencing HIV antiretroviral therapy in Zimbabwe: a retrospective cohort study

Review

CRISPR/Cas9: a tool to eradicate HIV-1

Review

Evidence and implication of interventions across various socioecological levels to address pre-exposure prophylaxis uptake and adherence among men who have sex with men in the United States: a systematic review

Research

Determinants and reasons for switching anti-retroviral regimen among HIV-infected youth in a large township of South Africa (2002–2019)

Short report

Advanced HIV disease management practices within inpatient medicine units at a referral hospital in Zambia: a retrospective chart review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits